Icon

FEMARA (nda020726)- (2.5MG)

LETROZOLE NOVARTIS PHARMS
2.5MG
Yes No
2011-Jun-03 Expired
None None
None No
Femara is an aromatase inhibitor indicated for:  Adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer  Extended adjuvant treatment of postmenopausal women with early breast cancer who have received prior standard adjuvant tamoxifen therapy  First and second-line treatment of postmenopausal women with hormone receptor positive or unknown advanced breast cancer
7 1 6
Total Other Developers 8
Drugs with Suitability No
2.5MG ** ** - 5 -
NDA Sales Available Total Generic Sales Available
Yes 5
ANDA No Generic Co Manufacturer Name Operations Manufacturer Address Country
****** **** ****** ****** ****** ******* ******* *********** **** **. **-*-*, ***** ** ***** ********** ******, *****, ********, *** ******, ***** (***) ***
****** ****** ******** ***** *************** ******* *********** **** **. ***/***-****** / **** **.***/****-*********** , *******-***** ******* , ****** -******, ******, *********, ******* ******, ***** (***) ***
****** ******** **.*****'* ************ ******* *********** ** ** ** & ** ** **, ***** - ***, ****, *******,, *************, ****** ******* *** ***, ***** (***) ***
****** ***** ****** *** ***** ****** ******* *********** ****** ********, ******, **********, ********* *** ***, ***** (***) ***
****** ***** ****** *** ***** ****** ******* *********** **** **.: ** & **, ****, ***** ****** ****, ********, *************, ****** ******* ******, ***** (***) ***
****** ******* ****** ******* ****** ***-*********** ********** **.,***. *********** **.** **** ****, ******** ****, *****, *******, ******, ***** (***) ***
****** ***** ****** ***** ****** ************ ******* *********** ****-*, **. **. ***, *** & ***, ******* *******, ********* ******, *******-**********, ********* ******, ***** (***) ***

Download GenUS Drug Report


Download GenUS Detailed Report


To get detailed report Contact Us

GenUs Advanced Search





Expired
to
Expired
to


Please contact contact@researchdelta.com to get more details.